With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.13885-09-1,2-(Diphenylphosphino)biphenyl,as a common compound, the synthetic route is as follows.
A solution of CuI (0.019 g, 0.1 mmol) in CH3CN(5 mL) wasadded to a stirred solution of 2,2?-Bipy (0.016 g, 0.1 mmol)and 2-(Dpp)bp (0.034 g, 0.1 mmol) in CH3CN(5 mL). Themixture was stirred for 10 min, with no visible precipitation.After filtration, the clear filtrate was set aside for evaporationin air. Orange block crystals of complex 4 were obtainedafter several hours. Yield: 43.4 mg (63.4percent, based on Cu).Anal. Calc. for 4 C34H27N2P1Cu1I1:C, 59.63; H, 3.94; N,4.09. Found (percent): C, 59.64; H, 3.92; N, 3.98. IR (KBr pellet,cm?1): 3430sh, 3054vw, 1610m, 1431s, 1146w, 1103w,770, 699.
13885-09-1, As the paragraph descriping shows that 13885-09-1 is playing an increasingly important role.
Reference£º
Article; Chen, Di; Chai, Wen-Xiang; Song, Li; Transition Metal Chemistry; vol. 43; 6; (2018); p. 517 – 527;,
Phosphine ligand
Chiral phosphine ligands in asymmetric synthesis. Molecular structure and absolute configuration of (1,5-cyclooctadiene)-(2S,3S)-2,3-bis(diphenylphosphino)butanerhodium(I) perchlorate tetrahydrofuran solvate